Its role Owner
Genmab A/S is a Danish biotechnology company focused on the discovery and development of antibody-based therapeutics, primarily for oncology and immune-related diseases. Headquartered in Copenhagen, with operations in Europe, North America, and Asia, the company advances monoclonal and bispecific antibody technologies through in-house research and collaborations. Related entities include Genmab Holding II B.V. and Genmab Finance LLC.
Genmab’s business model centers on proprietary antibody engineering platforms, co-development agreements, and licensing, generating revenue from research funding, milestones, and royalties. Antibodies discovered or developed by Genmab and commercialized with partners include daratumumab (marketed by Janssen, a Johnson & Johnson company, for multiple myeloma), epcoritamab (co-developed and co-commercialized with AbbVie for B-cell lymphomas), tisotumab vedotin (with Seagen for recurrent or metastatic cervical cancer), amivantamab (marketed by Janssen for certain EGFR-mutated lung cancers), and ofatumumab (licensed to Novartis, marketed as Kesimpta for multiple sclerosis). Genmab continues to expand its pipeline across hematologic malignancies and solid tumors through clinical trials and partnerships.
Also known as Genmab Holding II B.V. and Genmab Finance LLC.
chemXplore tracks 1 project involving Genmab.
Revenue rose 22% to $3,238m; epcoritamab approved in Europe and Japan; two Phase‑3 starts for petosemtamab in CRC; multiple Phase‑3 topline readouts were positive.
First interim IDMC readout from LiGeR‑HN1 shows a 50% reduction in risk of death and a >3‑fold increase in objective response for the combination versus pembrolizumab alone.
Combination therapy produced 28.2‑month median OS, 63% ORR and 9.0‑month mPFS in first‑line PD‑L1+ recurrent/metastatic head and neck cancer, with responses across HPV status.
EGFR/LGR5 bispecific plus FOLFOX or FOLFIRI showed confirmed/unconfirmed ORRs of 75% (1L) and 67% (2L), with 81% in 1L left‑sided tumors and manageable infusion‑related reactions.
Phase 1/2 trial will combine an EGFR/LGR5 bispecific antibody with a KRAS G12D inhibitor plus chemotherapy as first‑line treatment for KRAS G12D‑mutant metastatic colorectal cancer.
Phase 3 RAINFOL‑02 shows statistically significant and clinically meaningful PFS and OS benefits versus investigator’s choice chemotherapy in platinum‑resistant ovarian cancer.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
